• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Valganciclovir May Benefit Liver Transplant Patients

Article

In pediatric liver transplant patients who are infected with Epstein-Barr virus, treatment with valganciclovir may help clear the virus and decrease the risk of post-transplant lymphoproliferative disorder, according to the results of a study published in the August issue of Liver Transplantation.

THURSDAY, Aug. 7 (HealthDay News) -- In pediatric liver transplant patients who are infected with Epstein-Barr virus, treatment with valganciclovir may help clear the virus and decrease the risk of post-transplant lymphoproliferative disorder, according to the results of a study published in the August issue of Liver Transplantation.

Loreto Hierro, M.D., of Hospital Universitario La Paz in Madrid, Spain, and colleagues treated 47 children with valganciclovir (520 mg/sqm twice daily) starting a median of 17 months after the onset of Epstein-Barr virus infection.

After treating 26 patients for 30 days, the researchers found that Epstein-Barr virus was undetectable in 11 of 32 courses (34.3 percent). After treating 42 patients for a median of eight months, they found that Epstein-Barr virus was undetectable in 20 (47.6 percent). Although no new cases of post-transplant lymphoproliferative disorder were diagnosed, they observed worsening symptoms in one patient with suspected post-transplant lymphoproliferative disorder that was not confirmed in liver and jejunum biopsies.

"Given the relatively short follow-up of patients in their study and the fact that less than half of the patients treated with valganciclovir in their cohort experienced clearance of Epstein-Barr virus DNA, we agree with these investigators that additional trials of valganciclovir are needed to establish a beneficial effect of this drug," state the authors of an accompanying editorial.

AbstractFull Text (subscription or payment may be required)Editorial

Copyright © 2008 ScoutNews, LLC. All rights reserved.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Scott Ceresnak, MD
Scott Ceresnak, MD
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
© 2024 MJH Life Sciences

All rights reserved.